Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy

Fiona Russell, Paul Licciardi, Anne Balloch, Viema Biaukula, Lisi Tikoduadua, Jonathan Carapetis, Jane Nelson, Adam Jenney, Lepani Waqatakirewa, Samantha Colquhoun, Yin Cheung, Mimi Tang, Edward (Kim) MULHOLLAND

    Research output: Contribution to journalArticle

    Abstract

    Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p < 0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group. � 2010 Elsevier Ltd.
    Original languageEnglish
    Pages (from-to)3086-3094
    Number of pages9
    JournalVaccine
    Volume28
    Publication statusPublished - 2010

      Fingerprint

    Cite this

    Russell, F., Licciardi, P., Balloch, A., Biaukula, V., Tikoduadua, L., Carapetis, J., ... MULHOLLAND, E. K. (2010). Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine, 28, 3086-3094.